6 results on '"Rugeri, L."'
Search Results
2. MATERNAL AND NEONATAL AUTOIMMUNE THROMBOCYTOPENIA.
- Author
-
Allsup, D., Martlew, V., Galvani, D., Valat, A. S., Caulier, M. T., Devos, P., Rugeri, L., Vaast, P., Puech, F., Bauters, F., and Jude, B.
- Subjects
THROMBOCYTOPENIA ,MATERNAL-fetal exchange ,NEONATAL diseases - Abstract
Comments on an article about the relation between neonatal thrombocytopenia and maternal platelet count. Differential diagnosis for neonatal thrombocytopenia; Treatment approach to neonatal thrombocytopenia.
- Published
- 1999
- Full Text
- View/download PDF
3. Acquired factor V inhibitor: a nation-wide study of 38 patients.
- Author
-
Goulenok T, Vasco C, Faille D, Ajzenberg N, De Raucourt E, Dupont A, Frere C, James C, Rabut E, Rugeri L, Schleinitz N, Sacré K, and Papo T
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents adverse effects, Autoantibodies immunology, Comorbidity, Cross Reactions, Factor V immunology, Female, Follow-Up Studies, France epidemiology, Hemorrhage epidemiology, Humans, Immunoglobulin G immunology, Immunoglobulins, Intravenous adverse effects, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents therapeutic use, Isoantibodies immunology, Male, Middle Aged, Prothrombin Time, Retrospective Studies, Risk, Factor V antagonists & inhibitors, Hemorrhage etiology
- Abstract
Acquired factor V inhibitor (AFVI) is an extremely rare disorder that may cause severe bleeding. To identify factors associated with bleeding risk in AFVI patients, a national, multicentre, retrospective study was made including all AFVI patients followed in 21 centres in France between 1988 and 2015. All patients had an isolated factor V (FV) deficiency <50% associated with inhibitor activity. Patients with constitutional FV deficiency and other causes of acquired coagulation FV deficiencies were excluded. The primary outcome was incident bleeding and factors associated with the primary outcome were identified. Thirty-eight (74 [36-100] years, 42·1% females) patients with AFVI were analysed. Bleeding was reported in 18 (47·4%) patients at diagnosis and in three (7·9%) during follow-up (7 [0·2-48.7] months). At diagnosis, FV was <10% in 31 (81·6%) patients. Bleeding at diagnosis was associated with a prolonged prothrombin time that strongly correlated with the AFVI level measured in plasma {r = 0·63, 95% confidence interval (CI) [0·36-0·80], P < 0·05}. Bleeding onset during follow-up was associated with a slow AFVI clearance (P < 0·001). The corresponding receiver operating characteristics curve showed that AFVI clearance was predictive of bleeding onset with an AFVI clearance of seven months with a sensitivity of 100% (95% CI: 29-100) and a specificity of 86% (95% CI: 57-98, P = 0·02). Kaplan-Meier analysis showed that AFVI clearance >7 months increased the risk of bleeding by 8 (95% CI: [0·67-97], P = 0·075). Prothrombin time at diagnosis and time for clearance of FV inhibitor during follow-up are both associated with bleeding in patients with AFVI., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
4. Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.
- Author
-
Bouttefroy S, Meunier S, Milien V, Boucekine M, Chamouni P, Desprez D, Harroche A, Hochart A, Thiercelin-Legrand MF, Wibaut B, Chambost H, and Rugeri L
- Subjects
- Adolescent, Adult, Cohort Studies, Female, Humans, Male, Retrospective Studies, Young Adult, Factor XIII Deficiency
- Abstract
This FranceCoag network study assessed 33 patients with congenital factor XIII (FXIII) deficiency presenting FXIII levels <10 iu/dl. Diagnosis was based on abnormal bleeding in 29 patients, a positive family history in 2, recurrent miscarriages in 1 and was fortuitous in 1. Eighteen patients (62·1%) presented life-threatening umbilical or intracranial haemorrhages (ICH). Seven of the 15 patients who experienced ICH were diagnosed but untreated, including 3 with secondary neurological sequelae. All pregnancies without prophylaxis (26/26) led to miscarriages versus 3/16 with prophylaxis. In patients exhibiting FXIII levels <10 iu/dl, prophylaxis could be discussed at diagnosis and at pregnancy. Further controlled prospective studies are needed., (© 2019 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
5. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study.
- Author
-
Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C, Bestion A, Desmurs-Clavel H, Ninet J, Gaucherand P, Rudigoz RC, Berland M, Champion F, and Trzeciak MC
- Subjects
- Adult, Anticoagulants therapeutic use, Body Mass Index, Confidence Intervals, Female, Heparin, Low-Molecular-Weight therapeutic use, Humans, Maternal Age, Pilot Projects, Postpartum Period, Pregnancy, Pregnancy Trimester, Third, Prospective Studies, Recurrence, Risk Assessment methods, Risk Factors, Thrombophilia diagnosis, Twins, Venous Thromboembolism etiology, Pregnancy Complications, Hematologic prevention & control, Thrombophilia complications, Venous Thromboembolism prevention & control
- Abstract
Patients with thrombophilia and/or a history of venous thromboembolism (VTE) exhibit a high risk of thrombosis during pregnancy. The present multicentre study prospectively assessed a prophylaxis strategy, based on a risk score, in pregnancies with increased risk of VTE. Among 286 patients included in the study, 183 had a personal history of VTE (63.98%) and 191 patients (66.8%) had a thrombophilia marker. Eighty nine (46.6%) thrombophilic women had a personal history of VTE. Patients were assigned to one of three prophylaxis strategies according to the risk scoring system. In postpartum, all patients received low molecular weight heparin (LMWH) prophylaxis for at least 6 weeks. In antepartum, LMWH prophylaxis was prescribed to 61.8% of patients with high risk of VTE. Among them, 37.7% were treated in the third trimester only and 24.1% were treated throughout pregnancy. In this cohort, one antepartum-related VTE (0.35%) and two postpartum-related VTE (0.7%) occurred. No case of pulmonary embolism was observed during the study period. The rate of serious bleeding was 0.35%. There was no evidence of heparin-induced thrombocytopenia or osteoporosis. The use of a risk score may provide a rational decision process to implement safe and effective antepartum thromboprophylaxis in pregnant women at high risk of VTE.
- Published
- 2009
- Full Text
- View/download PDF
6. Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia.
- Author
-
Valat AS, Caulier MT, Devos P, Rugeri L, Wibaut B, Vaast P, Puech F, Bauters F, and Jude B
- Subjects
- Chronic Disease, Female, Humans, Infant, Newborn, Platelet Count, Pregnancy, Prospective Studies, Purpura, Thrombocytopenic, Idiopathic surgery, Risk Factors, Splenectomy, Thrombocytopenia blood, Thrombocytopenia embryology, Pregnancy Complications, Hematologic, Purpura, Thrombocytopenic, Idiopathic complications, Thrombocytopenia congenital
- Abstract
In pregnant women with antecedents of autoimmune thrombocytopenia (AITP), no predictive factor for severe fetal thrombocytopenia has been identified. We evaluated the relationships between the course of the maternal disease before and during pregnancy and the risk of severe fetal thrombocytopenia, in 64 pregnant women with known chronic AITP antecedents, over a 12-year period. 28 pregnant women had undergone splenectomy before pregnancy and 17 experienced severe thrombocytopenia (< 50 x 10(9)/l) during pregnancy (monthly determination). Eight infants presented with severe thrombocytopenia at birth (12.5%), and four in the following days (6.25%). No severe haemorrhage was observed. Severe thrombocytopenia at birth was present in 57% (CI 95% 18-90%) of the infants born to mothers with severe pregnancy-associated thrombocytopenia and splenectomy antecedents, and in 0% (CI 95% 0-15%) of the infants born to mothers who presented none of these antecedents (P=0.001). In thrombocytopenic mothers the infant platelet counts at birth were positively correlated to the nadir maternal platelet count during the index pregnancy (r=0.42, P=0.0075). These results suggest that severe autoimmune disease is a risk factor for severe fetal thrombocytopenia, and that pregnant women with no antecedent of splenectomy nor severe thrombocytopenia during pregnancy have a very low risk of severe fetal thrombocytopenia.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.